ARCHIVES

NCI Breast Cancer Overview Report Competed

This article is from The Cancer Letter archive.

Vol. 14 No. 32 | August 5, 1988

Download PDF Visit The Full Archive

Related Articles

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

April 27, 2012

Dear FDA: Provenge Provokes Letters From Opponents, Advocates, Investors.

April 27, 2007

Dendreon’s Provenge Approved For Prostate Cancer Treatment

April 30, 2010

Cytopathologists, NCI Recommend New Method For Pap Smear Reports

August 25, 1989

Elias Zerhouni Nominated for NIH Director; Richard Carmona For Surgeon General

April 5, 2002

Also FDA clarifies data requirements for phase I IND applications.

April 29, 2005